AIDS
FDA Approves New Enhancements in the Rapid HIV Test
By MedMira Inc.
May 10, 2005, 19:59

MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF) the global market leader in rapid flow-through diagnostic technology, announced today that it has received approval from the United States Food and Drug Administration (FDA) to provide new features in its Reveal(TM) G2 Rapid HIV-1 Antibody Test.

These enhancements will continue to heighten the competitiveness of Reveal(TM) G2 in the marketplace and further increase customer satisfaction.

This latest FDA approval enables MedMira to provide external control material with an extended shelf-life and additional flexibility, answering the emerging challenges and needs of the market. US laboratory professionals are subject to strict quality control requirements, and MedMira's enhancement to the external controls will improve cost-effectiveness and versatility for the customer.

Reveal(TM) G2 is currently the fastest rapid HIV test, at only 3-minutes, available in the United States and according to an independent study by the US Centers for Disease Control and Prevention (CDC), is the number one rapid HIV test used in US hospitals.

"MedMira's compliance and technology team has, again, successfully navigated the complex US regulatory process. Our increasing experience in meeting the FDA's requirements will facilitate future expansion of our product line in the United States," said Hermes Chan, president and COO of MedMira.

Over 180,000 HIV testing locations, including laboratories and hospitals, conduct an estimated 28 million HIV tests each year in the United States. MedMira anticipates continued sales growth and expansion of its rapid flow- through testing platform in the United States.

All rights reserved by www.rxpgnews.com